Pharmaceutical giant Pfizer is facing new challenges. After its sales increased dramatically during the pandemic, it is now struggling with a drop in demand for Covid-19-related products. But activist investor Starboard Value, which has raised about $1 billion, has decided to step in and turn the company's fortunes around.
Starboard Value entered Pfizer with a clear goal: to return the company to the limelight. It's not yet clear exactly how Starboard will get involved in Pfizer, but one thing is clear - investor and analyst dissatisfaction with the company's post-pandemic results. In addition, Starboard has reached out to former top Pfizer executives Ian Read and Frank D'Amelio, who have expressed interest in working together, though their specific role in the future strategy is not yet known.
Pfizer, which nearly doubled its sales during the pandemic thanks to the success of its Covid-19 vaccine and treatment, has been struggling with a drop in demand since the downturn. In 2022, sales…
I don't think Pfizer is a quality company and I don't know if this change will help Pfizer. Personally, I'm pretty skeptical about this.